Insider · CIK 0001551891
Laura Shawver
director
Files at SPRY (ARS Pharmaceuticals, Inc.). First filing Dec 4, 2024, latest Apr 8, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 5
$0 bought, $5.0M sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRY: ARS Pharmaceuticals, Inc.
SPRYOct 9, 2026 · close 4.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 5Weak | ARS Pharmaceuticals, Inc. | $615k 50,002 shares | -19% | +26% from low-27% from high | |
| 4Weak | ARS Pharmaceuticals, Inc. | $560k 50,000 shares | -24% | +7% from low-38% from high | |
| 5Weak | ARS Pharmaceuticals, Inc. | $616k 50,000 shares | -19% | +17% from low-30% from high | |
| 4Weak | ARS Pharmaceuticals, Inc. | $555k 50,000 shares | -19% | +5% from low-37% from high | |
| 40Moderate | ARS Pharmaceuticals, Inc. | $2.7M 200,000 shares | -65% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | SPRY ARS Pharmaceuticals, Inc. | AGrant or award Stock Option (right to buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Jun 27, 2025 |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +22,509 | $4.85 | $109k | 232,855 | Apr 8, 2025 |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +27,493 | $4.85 | $133k | 260,348 | Apr 8, 2025 |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -50,002 | $12.30 | $615k | 210,346 | Apr 8, 2025 |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -22,509 | $0.00 | $0 | 51,555 | Apr 8, 2025 |
| Apr 7, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,493 | $0.00 | $0 | 24,062 | Apr 8, 2025 |
| Mar 5, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +400 | $4.85 | $1,940 | 210,746 | Mar 7, 2025 |
| Mar 5, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -400 | $11.00 | $4,400 | 210,346 | Mar 7, 2025 |
| Mar 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +49,600 | $4.85 | $241k | 259,946 | Mar 7, 2025 |
| Mar 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -49,600 | $11.21 | $556k | 210,346 | Mar 7, 2025 |
| Mar 5, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -400 | $0.00 | $0 | 123,664 | Mar 7, 2025 |
| Mar 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -49,600 | $0.00 | $0 | 74,064 | Mar 7, 2025 |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +9,064 | $3.15 | $29k | 219,410 | Feb 4, 2025 |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +40,936 | $4.85 | $199k | 260,346 | Feb 4, 2025 |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -50,000 | $12.31 | $616k | 210,346 | Feb 4, 2025 |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -9,064 | $0.00 | $0 | 0 | Feb 4, 2025 |
| Feb 3, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -40,936 | $0.00 | $0 | 124,064 | Feb 4, 2025 |
| Jan 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +50,000 | $3.15 | $158k | 260,346 | Jan 7, 2025 |
| Jan 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -50,000 | $11.10 | $555k | 210,346 | Jan 7, 2025 |
| Jan 6, 2025 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -50,000 | $0.00 | $0 | 9,064 | Jan 7, 2025 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +67,616 | $1.27 | $86k | 277,962 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +29,628 | $1.27 | $38k | 307,590 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -96,343 | $13.55 | $1.3M | 211,247 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -901 | $14.34 | $13k | 210,346 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +25,606 | $1.27 | $33k | 235,952 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +62,378 | $3.15 | $196k | 298,330 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -87,984 | $13.26 | $1.2M | 210,346 | Dec 4, 2024 |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +14,772 | $3.15 | $47k | 225,118 | Dec 4, 2024 |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -14,772 | $13.75 | $203k | 210,346 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -29,628 | $0.00 | $0 | 25,606 | Dec 4, 2024 |
| Dec 2, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -67,616 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,606 | $0.00 | $0 | 0 | Dec 4, 2024 |
| Dec 3, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -62,378 | $0.00 | $0 | 73,836 | Dec 4, 2024 |
| Dec 4, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -14,772 | $0.00 | $0 | 59,064 | Dec 4, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.